Genmab — September 2017
-
novo og bava fik sænkede anbefalinger - men ellers er der vist ikke noget, der kan forklare det meget sure pharma/biotek marked
-
New Ofatumumab trial CLL / SLL: Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab https://clinicaltrials.gov/ct2/show/NCT03280160
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

